Thursday, June 18

Browsing: druggable

Research

Salt-inducible kinases as druggable targets for immunotherapy of ovarian cancer

By NewsCancerMay 21, 20260

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.This is a summary…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Evaluating Bladder-Sparing Strategies and Key GU Data From ASCO 2026

Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study

First new US sunscreen ingredient since 1999 approved by FDA – a skin scientist explains how bemotrizinol works

Browsing: druggable

Salt-inducible kinases as druggable targets for immunotherapy of ovarian cancer

Evaluating Bladder-Sparing Strategies and Key GU Data From ASCO 2026

Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study

First new US sunscreen ingredient since 1999 approved by FDA – a skin scientist explains how bemotrizinol works

First-Line/Maintenance Ibrutinib Improves Survival in TP53-Mutated MCL

Evaluating Bladder-Sparing Strategies and Key GU Data From ASCO 2026

Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study

First new US sunscreen ingredient since 1999 approved by FDA – a skin scientist explains how bemotrizinol works

First-Line/Maintenance Ibrutinib Improves Survival in TP53-Mutated MCL

Latest Post

Evaluating Bladder-Sparing Strategies and Key GU Data From ASCO 2026

Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study

First new US sunscreen ingredient since 1999 approved by FDA – a skin scientist explains how bemotrizinol works

Subscribe to Updates

What's Hot

Browsing: druggable